CITIUS PHARMAC DL Boeing Bond
47N Stock | EUR 3.29 0.00 0.00% |
CITIUS PHARMAC DL holds a debt-to-equity ratio of 0.007. . CITIUS PHARMAC's financial risk is the risk to CITIUS PHARMAC stockholders that is caused by an increase in debt.
CITIUS |
Given the importance of CITIUS PHARMAC's capital structure, the first step in the capital decision process is for the management of CITIUS PHARMAC to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of CITIUS PHARMAC DL to issue bonds at a reasonable cost.
Popular Name | CITIUS PHARMAC Boeing Co 2196 |
Equity ISIN Code | US17322U2078 |
Bond Issue ISIN Code | US097023DG73 |
S&P Rating | Others |
Maturity Date | 4th of February 2026 |
Issuance Date | 4th of February 2021 |
Coupon | 2.196 % |
CITIUS PHARMAC DL Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
C 5240588 25 JAN 26 | US17327CAP86 | Details | |
C 3057 25 JAN 33 | US17327CAQ69 | Details | |
C 2014 25 JAN 26 | US17327CAN39 | Details | |
CITIGROUP INC | US17327CAM55 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
US17328WP446 | US17328WP446 | Details |
Understaning CITIUS PHARMAC Use of Financial Leverage
CITIUS PHARMAC's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures CITIUS PHARMAC's total debt position, including all outstanding debt obligations, and compares it with CITIUS PHARMAC's equity. Financial leverage can amplify the potential profits to CITIUS PHARMAC's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if CITIUS PHARMAC is unable to cover its debt costs.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. CITIUS PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 10 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.